Rezolute FY2025 EPS Estimate Raised by HC Wainwright

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for Rezolute in a note issued to investors on Thursday, May 15th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.91) for the year, up from their prior forecast of ($0.96). HC Wainwright currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for Rezolute's current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Rezolute's Q4 2025 earnings at ($0.20) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at ($1.14) EPS, FY2028 earnings at ($0.59) EPS and FY2029 earnings at ($0.40) EPS.

Several other analysts also recently issued reports on the stock. Craig Hallum raised shares of Rezolute to a "strong-buy" rating in a research note on Tuesday, February 4th. Wall Street Zen downgraded shares of Rezolute from a "hold" rating to a "sell" rating in a research note on Thursday. Wedbush reissued an "outperform" rating and issued a $12.00 price objective on shares of Rezolute in a research note on Wednesday, May 14th. JMP Securities raised their target price on shares of Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 13th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Rezolute in a research report on Monday, February 10th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $12.14.

Rezolute Trading Down 0.3%

Shares of NASDAQ:RZLT traded down $0.01 during trading on Monday, reaching $3.89. The company's stock had a trading volume of 431,957 shares, compared to its average volume of 587,753. Rezolute has a 12 month low of $2.22 and a 12 month high of $6.19. The firm's 50 day simple moving average is $3.27 and its two-hundred day simple moving average is $4.24. The stock has a market capitalization of $235.48 million, a PE ratio of -3.19 and a beta of 1.01.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05).

Insider Activity at Rezolute

In other Rezolute news, CEO Nevan C. Elam acquired 12,302 shares of the business's stock in a transaction that occurred on Thursday, March 27th. The shares were bought at an average cost of $2.85 per share, with a total value of $35,060.70. Following the completion of the acquisition, the chief executive officer now directly owns 224,119 shares in the company, valued at $638,739.15. This represents a 5.81% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Daron Evans acquired 10,000 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The shares were acquired at an average cost of $2.89 per share, for a total transaction of $28,900.00. Following the completion of the acquisition, the chief financial officer now owns 237,900 shares of the company's stock, valued at $687,531. This trade represents a 4.39% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 29,060 shares of company stock valued at $83,694 over the last ninety days. 18.39% of the stock is owned by company insiders.

Hedge Funds Weigh In On Rezolute

Several institutional investors have recently bought and sold shares of RZLT. JPMorgan Chase & Co. purchased a new position in Rezolute in the third quarter worth $42,000. Alpine Global Management LLC purchased a new position in Rezolute in the fourth quarter worth $54,000. Jeppson Wealth Management LLC purchased a new position in Rezolute in the first quarter worth $35,000. Paloma Partners Management Co purchased a new position in Rezolute in the first quarter worth $48,000. Finally, Point72 Asia Singapore Pte. Ltd. grew its holdings in Rezolute by 48.5% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company's stock worth $97,000 after purchasing an additional 6,470 shares during the last quarter. 82.97% of the stock is owned by hedge funds and other institutional investors.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.